Table 2: Effects of nonbiologic and biologic DMARDs on lipid levels in patients with RA.

CholesterolTGsRef(s)
TCLDLHDL

Conventional synthetic DMARDs
Methotrexate↑ or =↑ or =N/A[42]
Hydroxychloroquine/chloroquine↓ or =↓ or =↑ or =[44]
Sulfasalazine=N/A[43]

Biologic
Adalimumab↑ or ===[77]
Infliximab↑ or =[68]
Etanercept↑ or ↓↑ or ↓ [77, 78]
Golimumab[79]
Tocilizumab=[31, 77]
RituximabN/AN/AN/AN/A
Abatacept↑ or ==[80]

Targeted small-molecule DMARD
TofacitinibN/A[32, 81]

=, no change; ↑, increase; ↓, decrease; DMARD, disease-modifying antirheumatic drug; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N/A, not available; RA, rheumatoid arthritis; ref, reference; TC, total cholesterol; TG, triglyceride. data were available for leflunomide, anakinra, or certolizumab. and cholesterol levels were not studied in the RA rituximab clinical trials.